John R Fischer

Pharma M&A boost from expanded drug and service access, plus outsourcing trends

'We’ve seen several high-profile transactions in life sciences, resulting in big exits for investors in the private and public markets,' said Toby Sykes, managing director of Intermediate Capital Group.

KKR finds the glass still half full; plus L Catterton, RF Investment and TA Associates bet on pet healthcare

Private equity invested heavily in pet care in 2024.

Pet owners spent more on vet services in 2024, and so did PE investors

'There’s an opportunity to continue to take advantage of that increasing spending in the vet space, while also adding additional customers, services and capabilities,' said RF Investment Partners' Collin Abert.

Home-based care deals driven by chronic conditions, aging population, patient-directed care

Frazier Healthcare Partners, Waud Capital Partners and RiverGlade Capital are among the PE firms backing home-based care.

RedBird Capital, Bruin Capital bet on entertainment deals; Francisco Partners, Serent Capital seize opportunities in EHRs

Private equity deals in the entertainment sector gained considerable momentum in 2024.

Electronic health records attract private equity: 5 deals

Dragoneer Investment Group, Serent Capital and Francisco Partners are among the PE firms investing in EHR technology companies.

Advanced Diabetes Supply Group's add-on of US Med was key to scaling the business

Cardinal Health agreed to acquire ADSG from Court Square Capital for approximately $1.1bn.

Exclusive: Morgan Stanley Capital Partners to acquire another healthcare outsourced service provider

MSCP is buying Prescott’s from Atlantic Street Capital, PE Hub can reveal.

RiverGlade, InTandem see add-on potential in infusion services; BCLP’s Schwartz on healthcare dealmaking scrutiny in '25

Private equity bets on healthcare infusion services.

Skepticism of PE-backed healthcare deals likely to continue under next FTC chair

BCLP's David Schwartz: 'The FTC has invested heavily in understanding and tracking private equity dealmaking in healthcare, and I do not see those investments being discarded just because of a change in administration.'